
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7148053/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Expression of the Human Serotonin 5-HT7 Receptor Rescues Phenotype Profile and Restores Dysregulated Biomarkers in a Drosophila melanogaster Glioma Model. Cells, 2022, 11, 1281.	4.1	3
2	Serodolin, a β-arrestin–biased ligand of 5-HT <sub>7</sub> receptor, attenuates pain-related behaviors. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	5
3	The GTPase-activating protein-related domain of neurofibromin interacts with MC1R and regulates pigmentation-mediated signaling in human melanocytes. Biochemical and Biophysical Research Communications, 2021, 534, 758-764.	2.1	4
4	Defective Oligodendroglial Lineage and Demyelination in Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2021, 22, 3426.	4.1	11
5	Chemical Synthesis of TFF3 Reveals Novel Mechanistic Insights and a Gut-Stable Metabolite. Journal of Medicinal Chemistry, 2021, 64, 9484-9495.	6.4	8
6	Complementary Nuclear Magnetic Resonance-Based Metabolomics Approaches for Glioma Biomarker Identification in a <i>Drosophila melanogaster</i> Model. Journal of Proteome Research, 2021, 20, 3977-3991.	3.7	4
7	BRET Analysis of GPCR Dimers in Neurons and Non-Neuronal Cells: Evidence for Inactive, Agonist, and Constitutive Conformations. International Journal of Molecular Sciences, 2021, 22, 10638.	4.1	1
8	LINGO family receptors are differentially expressed in the mouse brain and form native multimeric complexes. FASEB Journal, 2020, 34, 13641-13653.	0.5	9
9	Bioluminescence Resonance Energy Transfer as a Method to Study Protein-Protein Interactions: Application to G Protein Coupled Receptor Biology. Molecules, 2019, 24, 537.	3.8	36
10	Mechanistic characterization of S 38093, a novel inverse agonist at histamine H3 receptors. European Journal of Pharmacology, 2017, 803, 11-23.	3.5	9
11	Pharmacomodulation of microRNA Expression in Neurocognitive Diseases: Obstacles and Future Opportunities. Current Neuropharmacology, 2017, 15, 276-290.	2.9	20
12	MicroRNAs in Neurocognitive Dysfunctions: New Molecular Targets for Pharmacological Treatments?. Current Neuropharmacology, 2017, 15, 260-275.	2.9	43
13	Enhanced responsiveness of <i>Ghsr</i> <sup>Q343X</sup> rats to ghrelin results in enhanced adiposity without increased appetite. Science Signaling, 2016, 9, ra39.	3.6	20
14	Physical interaction between neurofibromin and serotonin 5-HT <sub>6</sub> receptor promotes receptor constitutive activity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12310-12315.	7.1	71
15	Rational Design, Pharmacomodulation, and Synthesis of Dual 5-Hydroxytryptamine 7 (5-HT <sub>7</sub> )/5-Hydroxytryptamine 2A (5-HT <sub>2A</sub> ) Receptor Antagonists and Evaluation by [ <sup>18</sup> F]-PET Imaging in a Primate Brain. Journal of Medicinal Chemistry, 2015, 58, 8066-8096.	6.4	15
16	Targeting the <i>cis</i> â€dimerization of <scp>LINGO</scp> â€1 with low <scp>MW</scp> compounds affects its downstream signalling. British Journal of Pharmacology, 2015, 172, 841-856.	5.4	14
17	Cdk5 induces constitutive activation of 5-HT6 receptors to promote neurite growth. Nature Chemical Biology, 2014, 10, 590-597.	8.0	95
18	A fraction of neurofibromin interacts with PML bodies in the nucleus of the CCF astrocytoma cell line. Biochemical and Biophysical Research Communications, 2012, 418, 689-694.	2.1	9

#	Article	IF	CITATIONS
19	Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology, 2012, 220, 225-241.	3.1	50
20	Ciproxifan, a histamine H3-receptor antagonist / inverse agonist, modulates methamphetamine-induced sensitization in mice. European Journal of Neuroscience, 2011, 33, 1197-1204.	2.6	20
21	Modulation of prepulse inhibition and stereotypies in rodents: no evidence for antipsychotic-like properties of histamine H3-receptor inverse agonists. Psychopharmacology, 2010, 210, 591-604.	3.1	23
22	CSF Levels of the Histamine Metabolite tele-Methylhistamine are only Slightly Decreased in Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 861-871.	2.6	25
23	Effects of Betahistine at Histamine H <sub>3</sub> Receptors: Mixed Inverse Agonism/Agonism In Vitro and Partial Inverse Agonism In Vivo. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 945-954.	2.5	34
24	Pharmacological, neurochemical, and behavioral profile of JB-788, a new 5-HT1A agonist. Neuroscience, 2010, 169, 1337-1346.	2.3	5
25	Histamine H3 Receptor-Mediated Signaling Protects Mice from Cerebral Malaria. PLoS ONE, 2009, 4, e6004.	2.5	21
26	Recessive Isolated Growth Hormone Deficiency and Mutations in the Ghrelin Receptor. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4334-4341.	3.6	74
27	Autoregulation of McA-RH7777 Hepatoma Cell Proliferation by Histamine H3 Receptors. Journal of Pharmacology and Experimental Therapeutics, 2008, 326, 406-413.	2.5	20
28	Constitutive activity of the histamine H3 receptor. Trends in Pharmacological Sciences, 2007, 28, 350-357.	8.7	119
29	Histamine and Schizophrenia. International Review of Neurobiology, 2007, 78, 247-287.	2.0	38
30	Histamine H3 and dopamine D2 receptor-mediated [35S]GTPγ[S] binding in rat striatum: Evidence for additive effects but lack of interactions. Biochemical Pharmacology, 2007, 73, 1172-1181.	4.4	29
31	Brain histamine and schizophrenia: Potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochemical Pharmacology, 2007, 73, 1215-1224.	4.4	101
32	N-methyl-d-aspartate receptor antagonists enhance histamine neuron activity in rodent brain. Journal of Neurochemistry, 2006, 98, 1487-1496.	3.9	43
33	Compared pharmacology of human histamine H3 and H4 receptors: structure-activity relationships of histamine derivatives. British Journal of Pharmacology, 2006, 147, 744-754.	5.4	55
34	Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. Journal of Clinical Investigation, 2006, 116, 760-768.	8.2	298
35	Cloning and expression of the mouse histamine H3 receptor: evidence for multiple isoforms. Journal of Neurochemistry, 2004, 90, 1331-1338.	3.9	48
36	Search for Histamine H3Receptor Ligands with Combined Inhibitory Potency at HistamineN-Methyltransferase: ω-Piperidinoalkanamine Derivatives. Archiv Der Pharmazie, 2004, 337, 533-545.	4.1	15

#	Article	IF	CITATIONS
37	Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists. Bioorganic and Medicinal Chemistry, 2004, 12, 2727-2736.	3.0	18
38	4-(ω-(Alkyloxy)alkyl)-1H-imidazole Derivatives as Histamine H3Receptor Antagonists/Agonists. Journal of Medicinal Chemistry, 2004, 47, 2678-2687.	6.4	9
39	Meta-Substituted Aryl(thio)ethers as Potent Partial Agonists (or Antagonists) for the Histamine H3Receptor Lacking a Nitrogen Atom in the Side Chain§. Journal of Medicinal Chemistry, 2004, 47, 3264-3274.	6.4	9
40	Imidazole derivatives as a novel class of hybrid compounds with inhibitory histamine N-methyltransferase potencies and histamine hH3 receptor affinities. Bioorganic and Medicinal Chemistry, 2003, 11, 2163-2174.	3.0	28
41	Fluorescence resonance energy transfer to probe human M1 muscarinic receptor structure and drug binding properties. Journal of Neurochemistry, 2003, 85, 768-778.	3.9	64
42	Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, modulates the effects of methamphetamine on neuropeptide mRNA expression in rat striatum. European Journal of Neuroscience, 2003, 17, 307-314.	2.6	34
43	Novel Nonimidazole Histamine H3 Receptor Antagonists:  1-(4-(Phenoxymethyl)benzyl)piperidines and Related Compounds. Journal of Medicinal Chemistry, 2003, 46, 1523-1530.	6.4	34
44	Constitutive activity of the recombinant and native histamine H3 receptor. International Congress Series, 2003, 1249, 139-151.	0.2	2
45	Protean agonism at histamine H3 receptors in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11086-11091.	7.1	136
46	Development of a New Class of Nonimidazole Histamine H3 Receptor Ligands with Combined Inhibitory Histamine N-Methyltransferase Activity. Journal of Medicinal Chemistry, 2002, 45, 1128-1141.	6.4	67
47	Ciproxifan, a Histamine H <sub>3</sub> -Receptor Antagonist/Inverse Agonist, Potentiates Neurochemical and Behavioral Effects of Haloperidol in the Rat. Journal of Neuroscience, 2002, 22, 7272-7280.	3.6	89
48	Progress in the proxifan class: heterocyclic congeners as novel potent and selective histamine H3-receptor antagonists. European Journal of Pharmaceutical Sciences, 2002, 15, 367-378.	4.0	47
49	Effects of histamine H 3 receptor agonist and antagonist on histamine co-transmitter expression in rat brain. Journal of Neural Transmission, 2002, 109, 293-306.	2.8	17
50	Histamine H <sub>3</sub> â€receptorâ€mediated [ <sup>35</sup> S]GTPγ[S] binding: evidence for constitutive activity of the recombinant and native rat and human H <sub>3</sub> receptors. British Journal of Pharmacology, 2002, 135, 383-392.	5.4	117
51	Application of genomics to drug design: the example of the histamine H3 receptor. European Neuropsychopharmacology, 2001, 11, 441-448.	0.7	18
52	The Rat H3 Receptor: Gene Organization and Multiple Isoforms. Biochemical and Biophysical Research Communications, 2001, 280, 75-80.	2.1	69
53	Chromosomal mapping and organization of the human histamine H3 receptor gene. NeuroReport, 2001, 12, 321-324.	1.2	38
54	6 The Histamine H3 Receptor and its Ligands. Progress in Medicinal Chemistry, 2001, 38, 279-308.	10.4	41

#	Article	IF	CITATIONS
55	Changes in Histamine H3 Receptor Responsiveness in Mouse Brain. Journal of Neurochemistry, 2001, 74, 339-346.	3.9	21
56	Different antagonist binding properties of human and rat histamine H3 receptors. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 951-954.	2.2	51
57	Cloning and cerebral expression of the guinea pig histamine H3 receptor. NeuroReport, 2000, 11, 755-759.	1.2	107
58	Histamine H2 receptor gene variants: lack of association with schizophrenia. Molecular Psychiatry, 2000, 5, 159-164.	7.9	33
59	Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain. British Journal of Pharmacology, 2000, 131, 1247-1250.	5.4	140
60	High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature, 2000, 408, 860-864.	27.8	449
61	Novel Histamine H3-Receptor Antagonists with Carbonyl-Substituted 4-(3-(Phenoxy)propyl)-1H-imidazole Structures like Ciproxifan and Related Compounds. Journal of Medicinal Chemistry, 2000, 43, 3987-3994.	6.4	49
62	Development of FUB 181, a Selective Histamine H3-Receptor Antagonist of High Oralin Vivo Potency with 4-(?gv-(Arylalkyloxy)alkyl)-1H-imidazole Structure. Archiv Der Pharmazie, 1998, 331, 211-218.	4.1	26
63	Inhibition of histamine versus acetylcholine metabolism as a mechanism of tacrine activity. European Journal of Pharmacology, 1996, 315, R1-R2.	3.5	43
64	Histamine H3 receptor binding sites in rat brain membranes: modulations by guanine nucleotides and divalent cations. European Journal of Pharmacology, 1990, 188, 219-227.	2.6	82
65	Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Research, 1990, 523, 325-330.	2.2	224
66	H3-Receptors Control Histamine Release in Human Brain. Journal of Neurochemistry, 1988, 51, 105-108.	3.9	144
67	Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature, 1983, 302, 832-837.	27.8	1,526